• KOL
    • Primary Insomnia
    • Thomas G Roth
    • Thomas G Roth: Influence Statistics

      Thomas G Roth

      Thomas G Roth

      Show email address

      Thomas Roth Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI, USA | Henry Ford Hospital, Detroit, MI, USA | Sleep Disorders and Research Center, Henry ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Thomas G Roth:Expert Impact

      Concepts for whichThomas G Rothhas direct influence:Primary insomnia,Sleep disorders,Daytime sleepiness,Transient insomnia,Excessive sleepiness,Rebound insomnia,Sleep latency,Sleep disturbance.

      Thomas G Roth:KOL impact

      Concepts related to the work of other authors for whichfor which Thomas G Roth has influence:Sleep quality,Insomnia symptoms,Restless legs syndrome,Shift work,Chronic pain.

      KOL Resume for Thomas G Roth

      Year
      2022

      Thomas Roth Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI, USA

      2021

      Sleep Disorders Center, Henry Ford Hospital, Detroit, MI, USA

      2020

      Thomas Roth Sleep Disorders & Research Center, Division of Sleep Medicine, Henry Ford Health System, Detroit, MI 48202 USA.

      Sleep Disorder & Research Center, Henry Ford Health System, Detroit, MI, USA

      Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, Michigan.

      2019

      Sleep Disorders and Research Center, Henry Ford Health System, Detroit, MI 48202, USA;,

      Henry Ford Health System, Wayne State University School of Medicine, Detroit, Michigan.

      Department of Psychiatry and Behavioral Neuroscience, SOM, Wayne State University, Detroit, Michigan

      2018

      Henry Ford Sleep Research Center, Henry Ford Hospital, Detroit, MI.

      Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI

      2017

      Henry Ford Hospital Sleep Center, Detroit, MI

      Professor, Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut

      Lowell W. and Josephine Q. Berry Professor of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Sleep Sciences and Medicine, Stanford, California

      2016

      Merck & Co., Inc., Kenilworth, NJ, (Dr Connor, Ms Mahoney, Ms Jackson, Ms Hutzelmann, Dr Zhao, Dr Jia, Dr Snyder, Mr Snavely, Dr Michelson, and Dr Herring);, Henry Ford Hospital, Detroit, MI, (Dr Roth).

      Sleep Center, Henry Ford Hospital, Detroit, Michigan, USA

      Henry Ford Hospital, Detroit, MI.

      Current affiliations:, Biogen, Cambridge, MA (E.M.)., Janssen Pharmaceutical Research and Development, Raritan, NJ (X.Z.)., Eli Lilly and Company, Indianapolis, IN (N.J.)

      2015

      Sleep Disorders Center, Henry Ford Health System, Detroit, MI, United States

      Department of Psychiatry and Behavioral Neuroscience, School of Medicine, Wayne State University, Detroit, Michigan, USA

      Henry Ford Health Systems, Detroit, Michigan

      2014

      Department of Pulmonary and Critical Care Medicine, Section of Sleep Medicine, Henry Ford Hospital, Detroit, Michigan, USA

      From the *Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; †Centre for Human Psychopharmacology, Swinburne University, Melbourne, Victoria, Australia; and ‡Sleep Disorders and Research Center, Henry Ford Health System, Detroit, MI.

      Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI

      Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Thomas G Roth is among the top experts in the world.
      Concept World rank
      month polysomnography points #1
      auto psg #1
      sleep latency tests #1
      shorter sleep latencies #1
      phase iii suvorexant #1
      disturbance hyperarousal #1
      gaboxadol studies #1
      evidence residual effects #1
      ethanol sleep extension #1
      patients sleep maintenance #1
      258 individuals #1
      sleep reactivity effects #1
      placebo 75 #1
      shift work role #1
      light task ethanol #1
      model transient insomnia #1
      periodiclimbmovement #1
      seconds training session #1
      hyperarousal postmenopausal women #1
      older subjects age #1
      shifts hour #1
      morning sedation #1
      sleep quality weeks #1
      sedatives male #1
      recovery fm #1
      nrs dis #1
      insomniacs administration #1
      differ placebo #1
      participant 4 doses #1
      nights 1 #1
      ramelteon placebo #1
      insomnia familial risk #1
      familial aggregation vulnerability #1
      sleepy participants #1
      indenes gender differences #1
      nights discontinuation #1
      hypnotic insomniacs #1
      decision driving test #1
      sleepiness cohort #1
      mslt 5 #1
      indiplon lsopd #1
      doxepin 3 #1
      transient insomnia #1
      baseline eszopiclone #1
      histamine clinical effects #1
      ext opioid arthroplasty #1
      wakefulness adult #1
      mslt brecs #1
      tst placebo #1
      nights flurazepam #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Thomas G Roth

      KOL-Index: 18114

      BACKGROUND: Some patients with obstructive sleep apnea/hypopnea syndrome (OSA/HS) experience excessive sleepiness (ES) that might not resolve with nasal continuous positive airway pressure (nCPAP) treatment.

      OBJECTIVE: The aim of the present study was to assess the efficacy and tolerability of armodafinil 150 or 250 mg QD when used as adjunctive treatment for residual ES associated with OSA/HS in patients who are adherent to nCPAP therapy.

      METHODS: This 12-week, multicenter, ...

      Known for Patients Armodafinil | Sleep Apnea | Residual Excessive | Clinical Condition | Controlled Study
      KOL-Index: 18005

      BACKGROUND: Sleep problems and depression are highly prevalent in pregnancy. Nocturnal rumination has been linked to insomnia and depression in non-pregnant samples, but remains poorly characterized in pregnancy. This study explored relationships of depression and suicidal ideation with insomnia, short sleep, and nocturnal rumination in mid-to-late pregnancy.

      METHODS: In this study, 267 pregnant women were recruited from obstetric clinics and completed online surveys on sleep, ...

      Known for Suicidal Ideation | Nocturnal Rumination | Insomnia Depression | Short Sleep | Pregnant Women
      KOL-Index: 17795

      STUDY OBJECTIVES: to evaluate the efficacy and safety of doxepin 1 mg and 3 mg in elderly subjects with chronic primary insomnia.

      DESIGN AND METHODS: the study was a randomized, double-blind, parallel-group, placebo-controlled trial. Subjects meeting DSM-IV-TR criteria for primary insomnia were randomized to 12 weeks of nightly treatment with doxepin (DXP) 1 mg (n = 77) or 3 mg (n = 82), or placebo (PBO; n = 81). Efficacy was assessed using polysomnography (PSG), patient reports, and ...

      Known for Primary Insomnia | Efficacy Safety | Doxepin Dxp | Outpatient Trial | Sleep Laboratory
      KOL-Index: 15899

      OBJECTIVE: To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor [corrected] agonist) in subjects with chronic primary insomnia.

      METHODS: Randomized, multicenter, double-blind, placebo-controlled trial of nightly ramelteon treatment (8 mg or 16 mg) in adults (N=405) with primary chronic insomnia (DSM-IV-TR). Latency to persistent sleep (LPS), TST, sleep efficiency, wake time after sleep onset, and number of awakenings were measured by polysomnography. Subject-reported measures ...

      Known for Placebo Ramelteon | Chronic Insomnia | Lps Week | Sleep Onset | Efficacy Safety
      KOL-Index: 15766

      INTRODUCTION: Depression increases during menopause, and subclinical depressive symptoms increase risk for major depression. Insomnia is common among postmenopausal women and increases depression-risk in this already-vulnerable population. Recent evidence supports the efficacy of cognitive-behavioral therapy for insomnia (CBTI) to treat menopausal insomnia, but it remains unclear whether treating insomnia also alleviates co-occurring depressive symptoms and depressogenic features. This ...

      Known for Postmenopausal Women | Insomnia Cbti | Behavioral Therapy | Cognitive Arousal | Disorders Treatment
      KOL-Index: 15741

      BACKGROUND: Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months. We aimed to assess its clinical profile during and after 1 year of treatment.

      METHODS: We did a randomised, placebo-controlled, parallel-group trial at 106 investigational centres in the Americas, Australia, Europe, and South Africa from December, 2009, to August, 2011. Patients aged 18 years or older with primary insomnia by DSM-IV-TR criteria were assigned using a ...

      Known for Patients Suvorexant | Phase 3 | Insomnia Efficacy | 1 Year | Hypnotics Sedatives
      KOL-Index: 15391

      STUDY OBJECTIVES: To evaluate the efficacy and safety of doxepin 1, 3, and 6 mg in insomnia patients.

      DESIGN: Adults (18-64 y) with chronic primary insomnia (DSM-IV) were randomly assigned to one of four sequences of 1 mg, 3 mg, and 6 mg of doxepin, and placebo in a crossover study. Treatment periods consisted of 2 polysomnographic assessment nights with a 5-day or 12-day drug-free interval between periods. Efficacy was assessed using polysomnography (PSG) and patient-reported measures. ...

      Known for Doxepin 1 | 3 6 | Primary Insomnia | Efficacy Safety | Residual Sedation
      KOL-Index: 15201

      BACKGROUND: Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials.

      METHODS: Two randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in nonelderly (18-64 years) and elderly (≥65 years) patients with insomnia. Suvorexant doses of 40/30 mg (nonelderly/elderly) and 20/15 mg (nonelderly/elderly) were evaluated. The primary focus was 40/30 mg, with fewer patients randomized to 20/15 mg. There was an ...

      Known for Patients Insomnia | Month 1 | Persistent Sleep | 3 Trials | Trial Suvorexant
      KOL-Index: 15090

      IMPORTANCE: Narcolepsy, a disorder associated with HLA-DQB1*06:02 and caused by hypocretin (orexin) deficiency, is diagnosed using the Multiple Sleep Latency Test (MSLT) following nocturnal polysomnography (NPSG). In many patients, a short rapid eye movement sleep latency (REML) during the NPSG is also observed but not used diagnostically.

      OBJECTIVE: To determine diagnostic accuracy and clinical utility of nocturnal REML measures in narcolepsy/hypocretin deficiency.

      DESIGN, SETTING, AND ...

      Known for Patients Narcolepsy | Hypocretin Deficiency | Sleep Disorders | Npsg Mslt | Rapid Eye
      KOL-Index: 14890

      OBJECTIVES: Sleep disturbances are common in patients with gastroesophageal reflux disease (GERD). This study examined the effects of esomeprazole on nighttime heartburn, GERD-related sleep disturbances, sleep quality, work productivity, and regular activities.

      METHODS: This multicenter, randomized, double-blind, placebo-controlled trial included adults with GERD-associated sleep disturbances and moderate-to-severe nighttime heartburn (recorded by patient diary during screening). ...

      Known for Nighttime Heartburn | Sleep Quality | Work Productivity | Patients Esomeprazole | Controlled Trial
      KOL-Index: 14829

      OBJECTIVE: To assess the effect of pregabalin on polysomnographic (PSG) measures of sleep and patient-rated sleep, tiredness, and pain in fibromyalgia patients.

      METHODS: We performed a randomized, double-blind, placebo-controlled, 2-period crossover PSG study. Patients ages ≥18 years with fibromyalgia satisfied subjective and objective sleep disturbance criteria prior to randomization. Eligible patients were randomized (1:1) to pregabalin (300-450 mg/day) or placebo for crossover period ...

      Known for Pregabalin Placebo | Sleep Patients | 4 Weeks | Pain Fibromyalgia | 2 Period
      KOL-Index: 14572

      Most night workers are unable to adjust their circadian rhythms to the atypical hours of sleep and wake. Between 10% and 30% of shiftworkers report symptoms of excessive sleepiness and/or insomnia consistent with a diagnosis of shift work disorder (SWD). Difficulties in attaining appropriate shifts in circadian phase, in response to night work, may explain why some individuals develop SWD. In the present study, it was hypothesized that disturbances of sleep and wakefulness in ...

      Known for Circadian Phase | Shift Work Disorder | Individuals Swd | Light Melatonin | Work Schedule
      KOL-Index: 14069

      OBJECTIVE: Evaluate the efficacy of ramelteon, an MT/1MT2-receptor agonist, for the treatment of transient insomnia in healthy adults.

      DESIGN: Randomized, double-blind, placebo-controlled design using a model of transient insomnia related to sleeping in a novel environment.

      SETTING: Fourteen sleep research centers.

      PARTICIPANTS: Healthy adults (N=375; 228 women), aged 35 to 60 years, who had never previously slept in a sleep laboratory and had a reported usual sleep duration of 6.5 to ...

      Known for Persistent Sleep | Transient Insomnia | Healthy Adults | Mt1 Receptor | Ramelteon Latency
      KOL-Index: 13992

      STUDY OBJECTIVES: To evaluate the efficacy and safety of doxepin (DXP) 3 mg and 6 mg in adults diagnosed with primary insomnia.

      DESIGN AND METHODS: The study was a randomized, double-blind, parallel-group, placebo-controlled trial. Patients meeting DSM-IV-TR criteria for primary insomnia were randomized to 35 days of nightly treatment with DXP 3 mg (n=75), DXP 6 mg (n=73), or placebo (PBO; n=73), followed by 2 nights of single-blind PBO to evaluate discontinuation (DC) effects. Efficacy ...

      Known for Primary Insomnia | Efficacy Safety | Dxp 6 | Doxepin 3 | Early Morning Awakenings

      Key People For Primary Insomnia

      Top KOLs in the world
      #1
      Daniel J Buysse
      sleep quality chronic insomnia metabolic syndrome
      #2
      Charles M Morin
      chronic insomnia behavioral therapy maintenance disorders
      #3
      Dieter Wilhelm Riemann
      rem sleep primary insomnia mental disorders
      #4
      Charles F Reynolds III
      major depression complicated grief late life
      #5
      Thomas G Roth
      primary insomnia sleep disorders sodium oxybate
      #6
      Michael Lloyd Perlis
      chronic insomnia suicidal ideation cognitive behavioral therapy

      Thomas Roth Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI, USA | Henry Ford Hospital, Detroit, MI, USA | Sleep Disorders and Research Center, Henry Ford Health System, Detroit, MI, USA | Division of Sleep Medicine, Sleep Di

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.